The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) reached all time high today, Nov, 17 and still has $57.96 target or 37.00% above today’s $42.31 share price. This indicates more upside for the $1.47 billion company. This technical setup was reported by Barchart.com. If the $57.96 PT is reached, the company will be worth $543.90 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 450,781 shares traded hands. Aerie Pharmaceuticals Inc (NASDAQ:AERI) has risen 174.26% since April 15, 2016 and is uptrending. It has outperformed by 169.63% the S&P500.
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Ratings Coverage
Out of 10 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 10 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aerie Pharmaceuticals has been the topic of 20 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Cantor Fitzgerald reinitiated it with “Buy” rating and $44 target price in Friday, June 3 report. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, September 17. The firm earned “Buy” rating on Thursday, October 6 by Stifel Nicolaus. The rating was initiated by JMP Securities on Wednesday, September 9 with “Market Outperform”. The rating was initiated by Raymond James with “Strong Buy” on Wednesday, September 14. The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) earned “Buy” rating by Cantor Fitzgerald on Thursday, September 17. H.C. Wainwright initiated Aerie Pharmaceuticals Inc (NASDAQ:AERI) rating on Tuesday, September 20. H.C. Wainwright has “Buy” rating and $66 price target. As per Thursday, September 15, the company rating was maintained by RBC Capital Markets. The firm has “Buy” rating by Aegis Capital given on Tuesday, November 1. The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) earned “Buy” rating by Needham on Thursday, September 15.
According to Zacks Investment Research, “Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It is focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s lead Dual- Action product and Triple-Action products are under developmental stages. Aerie Pharmaceuticals, Inc. is headquartered in Bedminster, New Jersey.”
Insitutional Activity: The institutional sentiment increased to 1.67 in 2016 Q2. Its up 0.28, from 1.39 in 2016Q1. The ratio is positive, as 11 funds sold all Aerie Pharmaceuticals Inc shares owned while 22 reduced positions. 9 funds bought stakes while 46 increased positions. They now own 26.15 million shares or 2.97% more from 25.39 million shares in 2016Q1.
Blackrock Inv Management holds 93,699 shares or 0% of its portfolio. Granite Point Mgmt L P reported 56,225 shares or 0.42% of all its holdings. State Board Of Administration Of Florida Retirement System holds 24,578 shares or 0% of its portfolio. Rice Hall James Associate Limited Liability Co has 0.16% invested in the company for 158,932 shares. Wellington Mgmt Grp Incorporated Llp, a Massachusetts-based fund reported 3.21 million shares. Blackrock Advsrs Ltd Liability has 12,310 shares for 0% of their US portfolio. Foresite Cap Mgmt Ii Limited Liability accumulated 11.73% or 975,285 shares. Jennison Assocs Lc last reported 3.71M shares in the company. The Minnesota-based Ameriprise Financial Inc has invested 0% in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Credit Suisse Ag has 36,693 shares for 0% of their US portfolio. Ny State Common Retirement Fund reported 32,547 shares or 0% of all its holdings. Vanguard Gp Inc owns 1.01M shares or 0% of their US portfolio. Voya Investment Lc reported 10,632 shares or 0% of all its holdings. Parametric Port Assocs Ltd Company owns 46,994 shares or 0% of their US portfolio. Manchester Management Limited Liability Corp last reported 0% of its portfolio in the stock.
Insider Transactions: Since July 22, 2016, the stock had 1 insider purchase, and 0 sales for $4.38 million net activity. The insider Foresite Capital Management II – LLC bought $4.38M.
Another recent and important Aerie Pharmaceuticals Inc (NASDAQ:AERI) news was published by Investorplace.com which published an article titled: “3 Stocks to Watch Thursday: Viacom, Inc. (VIAB), Aerie Pharmaceuticals Inc …” on September 15, 2016.
AERI Company Profile
Aerie Pharmaceuticals, Inc., incorporated on June 22, 2005, is a clinical-stage pharmaceutical company. The Firm is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan. The Company’s product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.